Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ATTR
Biotech
Bayer pays $310M for Europe rights to BridgeBio's Vyndaqel rival
With the FDA mulling whether to approve acoramidis as a rival to Pfizer’s Vyndaqel, Bayer is paying $310 million to scoop up the European rights.
James Waldron
Mar 4, 2024 8:22am
AstraZeneca's heart disease trial hits, teeing up Pfizer clash
Feb 2, 2024 6:43am
BridgeBio taps investors for $1.25B to fund showdown with Pfizer
Jan 18, 2024 8:04am
BridgeBio lifts the hood on phase 3 acoramidis data
Aug 28, 2023 11:21am
BridgeBio heart disease med vindicated with phase 3 victory
Jul 17, 2023 10:12am
Ionis, AstraZeneca crack open phase 3 data of Alnylam rival
Apr 24, 2023 7:00am